American Journal of Cardiology
Volume 103, Issue 3 , Pages 307-311 , 1 February 2009

Relation of Death Within 90 Days of Non-ST-Elevation Acute Coronary Syndromes to Variability in Electrocardiographic Morphology

  • Zeeshan Syed, MEng

      Affiliations

    • Harvard-MIT Division of Health Sciences and Technology, Cambridge, Massachusetts
    • MIT Department of Electrical Engineering and Computer Science, Cambridge, Massachusetts
    • ,
  • Benjamin M. Scirica, MD, MPH

      Affiliations

    • TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts
    • ,
  • Satishkumar Mohanavelu, MS

      Affiliations

    • TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts
    • ,
  • Phil Sung, SB

      Affiliations

    • MIT Department of Electrical Engineering and Computer Science, Cambridge, Massachusetts
    • ,
  • Eric L. Michelson, MD

      Affiliations

    • AstraZeneca LP, Wilmington, Delaware
    • ,
  • Christopher P. Cannon, MD

      Affiliations

    • TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts
    • ,
  • Peter H. Stone, MD

      Affiliations

    • TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts
    • ,
  • Collin M. Stultz, MD, PhD

      Affiliations

    • Harvard-MIT Division of Health Sciences and Technology, Cambridge, Massachusetts
    • MIT Department of Electrical Engineering and Computer Science, Cambridge, Massachusetts
    • ,
  • John V. Guttag, PhD

      Affiliations

    • MIT Department of Electrical Engineering and Computer Science, Cambridge, Massachusetts
    • Corresponding Author InformationCorresponding author: Tel: 617-253-6022; fax: 617-253-8460

Received 28 July 2008 ,Revised 12 September 2008 ,Accepted 12 September 2008.

References 

  1. Syed Z, Scirica BM, Stultz CM, Guttag JV. Risk-stratification following acute coronary syndromes using a novel electrocardiographic technique to measure variability in morphology. Comput Cardiol. 2008;(forthcoming)
  2. Cannon CP, Husted S, Harrington RA, Scirica BM, Emanuelsson H, Peters G, et al. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome. J Am Coll Cardiol. 2007;50:1844–1851
  3. deChazal P, O'Dwyer M, Reilly R. Automatic classification of heartbeats using ECG morphology and heartbeat interval features. IEEE Trans Biom Eng. 2004;51;:1196–1206
  4. Donoho D. Denoising by soft-thresholding. IEEE Trans Inf Theory. 2005;41:613–627
  5. Li Q, Mark RG, Clifford GD. Robust heart rate estimate fusion using signal quality indices and a Kalman filter. Physiol Meas. 2008;29:15–32
  6. Rabiner L. Considerations in dynamic time-warping algorithms for discrete word recognition. IEEE Trans Sig Proc. 1978;26:575–582
  7. Cormen TH, Leiserson CE, Rivest RL, Stein C. Introduction to Algorithms. 2nd ed.. MIT Press and McGraw Hill; 2001;
  8. Heart rate variability: standards of measurement, physiological interpretation, and clinical use: Task Force of the European Society of Cardiology the North American Society of Pacing Electrophysiology. Circulation. 1996;93:1043–1065
  9. Ohman E, Granger C, Harrington R, Lee K. Risk stratification and therapeutic decision-making in acute coronary syndromes. JAMA. 2000;284:876–878
  10. Acar B, Yi G, Hnatkova K, Malik M. Spatial, temporal and wavefront direction characteristics of 12-lead T-wave morphology. Med Biol Eng Comput. 1999;37:574–584
  11. Zabel M, Acar B, Klingenheben T, Franz MR, Hohnloser SH, Malik M. Analysis of 12-lead T-wave morphology for risk stratification after myocardial infarction. Circulation. 2000;102:1252–1257

 This work was supported, in part, by Center for Integration of Medicine and Innovative Technology, Harvard-MIT Division of Health Sciences and Technology, and Industrial Technology Research Institute (Taiwan). The DISPERSE2 trial was supported by AstraZeneca.

PII: S0002-9149(08)01676-7

doi: 10.1016/j.amjcard.2008.09.099

American Journal of Cardiology
Volume 103, Issue 3 , Pages 307-311 , 1 February 2009

Article Tools

* Image Usage & Resolution